Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170. Zinzani PLL, Thieblemont C, Melnichenko V, Bouabdallah K, et al. Blood 2023 May 2:blood.2022019340. doi: 10.1182/blood.2022019340.

Read + Share

Amedeo Smart

Independent Medical Education

Zinzani PLL, Thieblemont C, Melnichenko V, Bouabdallah K, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170. Blood 2023 May 2:blood.2022019340. doi: 10.1182/blood.2022019340.
PMID: 37130017